Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

16.17USD
21 Feb 2018
Change (% chg)

$-0.54 (-3.23%)
Prev Close
$16.71
Open
$16.69
Day's High
$16.91
Day's Low
$16.16
Volume
419,032
Avg. Vol
733,779
52-wk High
$55.28
52-wk Low
$15.29

Chart for

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $3,479.97
Shares Outstanding(Mil.): 97.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Paulson & Co Cuts Share Stake In Mallinckrodt PLC

* PAULSON & CO CUTS SHARE STAKE IN MALLINCKRODT PLC TO 3.7 MILLION SHARES FROM 6.6 MILLION SHARES - SEC FILING

15 Feb 2018

BRIEF-Mallinckrodt Enrolls First Patient In Phase 1 Study Of Skin Tissue

* MALLINCKRODT ENROLLS FIRST PATIENT IN PHASE 1 STUDY OF EXPRESSGRAFT™C9T1 SKIN TISSUE Source text for Eikon: Further company coverage:

14 Feb 2018

BRIEF-Mallinckrodt Says Units Entered A $600 Million Senior Secured Term Loan Facility

* MALLINCKRODT PLC SAYS ON FEB 13, IN CONNECTION WITH THE MERGER, UNITS OF CO ENTERED INTO A $600 MILLION SENIOR SECURED TERM LOAN FACILITY- SEC FILING

13 Feb 2018

BRIEF-First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar Gel For Pulmonary Sarcoidosis

* FIRST PATIENT ENROLLED IN MALLINCKRODT PHASE 4 TRIAL OF H.P. ACTHAR® GEL (REPOSITORY CORTICOTROPIN INJECTION) FOR PULMONARY SARCOIDOSIS Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln

* MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS

08 Jan 2018

BRIEF-Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility

* MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING

05 Jan 2018

BRIEF-Mallinckrodt Completes Stannsoporfin New Drug Application Filing

* MALLINCKRODT COMPLETES STANNSOPORFIN NEW DRUG APPLICATION FILING Source text for Eikon: Further company coverage:

05 Jan 2018

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

26 Dec 2017

UPDATE 2-Mallinckrodt to buy Sucampo for about $840 mln

* Deal for $18/share, a premium of about 6 pct to Friday close

26 Dec 2017

BRIEF-Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million

* SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING Source text : (http://bit.ly/2BUtNpK) Further company coverage:

26 Dec 2017

Competitors

  Price Chg
Meda AB (MEDAa.ST) -- --
Merck KGaA (MRCG.DE) €82.34 -1.16
AB Science SA (ABS.PA) €8.30 -0.19

Earnings vs. Estimates